Ubiquitin C (UBC) is a critical polyubiquitin precursor gene that maintains cellular ubiquitin homeostasis, particularly under proteotoxic stress. As a foundational pillar of the Ubiquitin-Proteasome System (UPS), UBC-derived ubiquitin monomers are indispensable for protein degradation, cell cycle regulation, and DNA damage response. The therapeutic exploitation of this pathway—ranging from targeted protein degradation (PROTACs/Molecular Glues) to Deubiquitinase (DUB) inhibitors—demands highly characterized, sequence-verified ubiquitin mutants and assay reagents to map complex polyubiquitination networks.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UBC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBC Recombinant Protein (Wild-Type & Mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View UBC Products |
| Gene Delivery | UBC Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View UBC Products |
| Benchmark Ab | Anti-UBC (Recombinant Positive Control) Sequence-verified benchmark antibody for western blot and ELISA. |
View UBC Products |
| Validator | UBC siRNA Set For knockdown verification and proteotoxic stress studies. |
View UBC Products |
| Related Target A | USP7 Deubiquitinating enzyme regulating p53 stability; key target for UPS-based oncology. |
View USP7 Products |
| Related Target B | CRBN Primary E3 ligase substrate receptor utilized in PROTAC and molecular glue design. |
View CRBN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating chain linkage specificity (K48 vs K63) | Recombinant UBC Single-Lysine Mutants strictly verified by mass spectrometry and theoretical MW. |
| Subfamily and Ubiquitin-like (UBL) cross-screening | Homolog panel including SUMO and NEDD8 proteins with >95% purity for counter-screening. |
| Lack of standardized assay controls | Clinical-grade benchmark antibodies and validated siRNA sets included in the portfolio. |
| In vitro assay false positives | Endotoxin-controlled, E. coli or HEK293-expressed proteins minimizing non-specific cellular reactions. |
Live UBC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UBC therapeutics is intensifying, with major players shifting focus from traditional proteasome inhibitors to targeted protein degradation (TPD) and specific E3 ligase/DUB modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting the selective inhibition of stress-induced ubiquitin upregulation (via UBC knockdown) and the engineering of linkage-specific PROTACs to bypass tumor resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Arvinas, Bristol Myers Squibb | Prostate Cancer, Multiple Myeloma | Ubiquitination Kinetic Assays (Need Mutant UBC Proteins) |
| DUB Inhibitors | Mission Therapeutics, Ubiquigent | Neurodegeneration, Oncology | Deubiquitination Validation (Need Linkage-Specific UBC Chains) |
| RNAi / ASO | Alnylam, Ionis | Refractory Solid Tumors | Expression Knockdown Assays (Need Validated UBC siRNA) |